Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOTUM•070 is a patented, polyphenol-rich active substance composed of a blend of five plant extracts. It is developed as a clinically validated, non-pharmaceutical dietary supplement for the management of mild to moderate hypercholesterolemia. The product has demonstrated significant lipid-lowering effects in both preclinical and clinical studies, including reductions in LDL cholesterol, total cholesterol, non-HDL cholesterol, and triglycerides. Its mechanism involves multi-targeted actions at both the intestinal level (reducing cholesterol absorption) and hepatic level (inhibiting de novo cholesterol synthesis), with additional benefits on liver health such as decreased lipid storage and reduced expression of inflammatory markers. The supplement also positively modulates gut microbiota composition. Developed by Valbiotis, it is intended for over-the-counter use without prescription and targets individuals not eligible or recommended for pharmaceutical statins or other drug therapies[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TOTUM•070.